Frontiers in Psychiatry
April 23, 2024
Kennadi Johnson, A. Weldon, Melissa A. Burmeister
Schizophrenia is a serious mental health disorder that confers one of the highest mortality rates of all psychiatric illnesses. Although the disorder’s psychotic symptoms are treatable with conventional antipsychotics, they remain incurable. Moreover, medication adherence is poor, and individuals with schizophrenia choose to self-medicate with illicit substances, including cannabis. It is...
Scientific Reports
April 22, 2024
Oleh Durydivka, Petr Palivec, Matej Gazdarica et al.
7 citations
Abstract The Cannabis sativa plant has been used for centuries as a recreational drug and more recently in the treatment of patients with neurological or psychiatric disorders. In many instances, treatment goals include relief from posttraumatic disorders, anxiety, or to support treatment of chronic pain. Ligands acting on cannabinoid receptor 1 (CB1R) are also potential targets for the...
BMC Psychiatry
April 19, 2024
Feten Fekih Romdhane, Amthal Alhuwailah, Hanaa Shuwiekh et al.
4 citations
BACKGROUND: Public education efforts to address and reduce potential harms from cannabis use in Arab countries are either slow or inexistent, and do not follow the steadily increasing trends of cannabis use in Arab youth. Several decades of research on substance use, it can be suggested that being aware of, and knowing about, psychosis risk related to cannabis can at least limit the consumption...
European Psychiatry
April 1, 2024
O. Martin-Santiago, M. Calvo-Valcarcel, P. Martinez.Gimeno et al.
Introduction Epidemiological studies have established a complex relationship between cannabis consumption and a heightened risk of psychotic disorders, including schizophrenia. However, this connection is multifaceted, influenced by genetics, environment, and individual psychology. Surprisingly, despite a surge in emergency room (ER) visits associated with cannabis consumption and psychosis,...
European Psychiatry
April 1, 2024
E. Bergaoui, R. Lansari, O. Chehaider et al.
IntroductionThe use of cannabis is associated with developing psychotic disorders, especially for those with a pre-existing vulnerability and elevated familial risk for psychosis.ObjectivesTo assess cannabis use during first episode psychosis and its relationship with patients’ clinical symptoms and functioning.MethodsWe assessed 50 patients hospitalized for first episode psychosis using three...
JAMA Psychiatry
March 13, 2024
Otto Simonsson, Miriam A. Mosing, Walter Osika et al.
41 citations
Importance While psychedelic-assisted therapy has shown promise in the treatment of certain psychiatric disorders, little is known about the potential risk of psychotic or manic symptoms following naturalistic psychedelic use, especially among adolescents. Objective To investigate associations between naturalistic psychedelic use and self-reported psychotic or manic symptoms in adolescents...
Theoretical and Natural Science
March 5, 2024
Hou-Yu Zhao, Kun Liang, Yiqun Fang
Military personnel and veterans experience distinct trauma exposures, resulting in totally different mental disorder prevalence, comorbidities, and treatment responses compared to the general population. The medical use of psychoactive substances as novel strategies for specific mental health conditions within military contexts is being investigated, while their therapeutic efficacy and safety...
Behavioral Sleep Medicine
March 3, 2024
Alannah Miranda, Elizabeth Peek, Sonia Ancoli-Israel et al.
Both sleep and cognition are partially modulated by the endocannabinoid (ECB) system. Cannabis has been reported to have effects on sleep and cognition. This review aims to summarize the recent literature on the ECB system, the role of cannabis and the ECB system on sleep regulation and cognition. Further, this review will identify existing gaps in knowledge and suggest potential targets for...
Brain Sciences
March 3, 2024
Mario Renato Velit-Salazar, Eloise Cherian, Paulo R Shiroma
13 citations
Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among healthy individuals and patients with post-traumatic stress disorder (PTSD) or major depressive disorder (MDD). Methods: The Preferred Reporting Items for Systematic Reviews (PRISMA) was used as a guide to structure and report the findings for this review. A...
Cureus
March 1, 2024
Edward E. Denton, Sophia S. Jung, C. A. I. Ventura
Cannabis-induced psychosis (CIP) is an increasingly acknowledged psychiatric phenomenon observed in vulnerable patients exposed to cannabis. This brief case report details a male patient in his 20s, who presents to the ED with derealization two days after ingesting a gummy worm containing delta-8-tetrahydrocannabinol (Δ8-THC). Two days post-ED discharge, the patient gradually developed symptoms...
Psychopharmacology
February 28, 2024
Daniel L. Hall, Will Lawn, Shelan Ofori et al.
5 citations
RATIONALE: Attentional bias to drug-related stimuli is hypothesised to contribute towards addiction. However, the acute effects of Δ9-tetrahydrocannabinol (THC) on attentional bias to cannabis cues, the differential response in adults and adolescents, and the moderating effect of cannabidiol (CBD) are unknown. OBJECTIVES: Our study investigated (1) the acute effects of vaporised cannabis on...
Reviews in the Neurosciences
February 26, 2024
Bárbara Dos Anjos Rosário, Jéssica Alves Lemes, Maria Paula De Lima et al.
Social anxiety disorder (SAD) is a debilitating disorder, characterized by fear and anxiety in social situations. Evidence suggests that the levels of SAD are rising, in particularly after the COVID-19 pandemic. Serotonin and noradrenaline reuptake inhibitors and cognitive-behavioral therapy are effective treatments for SAD. Nevertheless, a significant number of patients do not respond well to...
Medical Cannabis and Cannabinoids
February 23, 2024
Alexander Beletsky, Cherry Liu, Bryson Lochte et al.
Abstract Introduction: Cannabis has been reported to have both anxiogenic and anxiolytic effects. Habitual cannabis use has been associated with anxiety disorders (AD). The causal pathways and mechanisms underlying the association between cannabis use (CU)/cannabis use disorder (CUD) and anxiety remain unclear. We examined the literature via a systematic review to investigate the link between...
Journal of Cannabis Research
February 3, 2024
Ashley Brooks-Russell, Julia Wrobel, Tim Brown et al.
Background Acute cannabis use has been demonstrated to slow reaction time and affect decision-making and short-term memory. These effects may have utility in identifying impairment associated with recent use. However, these effects have not been widely investigated among individuals with a pattern of daily use, who may have acquired tolerance. The purpose of this study was to examine the impact...
Addiction
February 2024
Dominic Oliver, Amir Englund, Edward Chesney et al.
To test how attentional bias and explicit liking are influenced by delta-9-tetrahydrocannabinol (THC) and whether these effects are moderated by cannabidiol (CBD). Double-blind, randomised, within-subjects cross-over study. NIHR Wellcome Trust Clinical Research Facility at King's College Hospital, London, United Kingdom. Forty-six infrequent cannabis users (cannabis use <1 per week). Across...
Cannabis and Cannabinoid Research
February 1, 2024
Catharine A. Mielnik, Chun Kit Li, Amy J. Ramsey et al.
Introduction: Cannabis use has been associated with an increased incidence of psychiatric disorders, yet the underlying neurobiological processes mediating these associations are poorly understood. Whereas exposure to Δ9-tetrahydrocannabinol (THC) has been associated with the development or exacerbation of psychosis, treatment with cannabidiol (CBD) has been associated with amelioration of...
Cannabis and Cannabinoid Research
February 1, 2024
Edward Chesney, Will Lawn, Philip Mcguire
Introduction: Cannabis use is common in people with psychotic disorders and is associated with the exacerbation of symptoms, poor treatment adherence, and an increased risk of relapse. Accurate assessment of cannabis use is thus critical to the clinical management of psychosis. Discussion: Cannabis use is usually assessed with self-report questionnaires that were originally developed for...
Cannabis and Cannabinoid Research
February 1, 2024
Laurel P Gibson, Raeghan L. Mueller, Evan A Winiger et al.
Background: The popularity of edible cannabis products continues to grow in states with legal cannabis access, but few studies have investigated the acute effects of these commercially available products. The present study sought to explore the effects of three commercially available edible products with different levels of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Methods: A...
Cannabis and Cannabinoid Research
February 1, 2024
Faiz M Kassim, Sophie Tod, Jennifer Rodger et al.
Background: Memory impairments and psychosis-like experiences can be adverse effects of cannabis use. However, reports on the cognitive impact of cannabis use are not consistent. There are also limited studies on the psychotomimetic effects of cannabinoid compounds to reveal the association between cannabis and psychosis. Therefore, we investigated the effect of acute cannabinoid intoxication...
Sociology
February 1, 2024
Isak Ladegaard
5 citations
Electronic drug markets enable calculative, impersonal trade between faceless strangers, but also intimate interaction between pseudonymous users. In this space, do people treat banned drugs as ordinary consumer products that can be purchased from anyone? Or do drug-takers frame their consumption as a counter-cultural activity? To answer these questions, I use qualitative and computational...